B
BioLineRx Ltd. (BLRX)
NCM – Real vaqt narxi. Valyuta: USD
3.11
+0.13 (4.36%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.04
-0.05 (-1.62%)
Bozor oldidan: May 13, 2026, 7:05 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
3.11
+0.13 (4.36%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.04
-0.05 (-1.62%)
Bozor oldidan: May 13, 2026, 7:05 AM EDT
BioLineRx Ltd., biopharmatsevtika kompaniyasi, onkologiya va kam uchraydigan kasalliklar uchun terapevtik vositalarni ishlab chiqadi va tijoratlashtiradi. Kompaniyaning klinik dasturi GLIX1, og'iz orqali qabul qilinadigan, kichik molekulali, glioblastoma va boshqa saraton turlarida DNK shikastlanishiga javob berishni maqsad qilgan; va APHEXDA (motixafortide), o'roq hujayrali anemiya davolash uchun 1-faza klinik sinovida va oshqozon osti bezi saratonini davolash uchun 2b-faza klinik sinovida bo'lgan peptidi, shuningdek, ko'p miyelomani davolash uchun 3-faza klinik sinovini tugatgan. U terining shikastlanishini jarrohliksiz olib tashlash uchun kislotali suvli eritmani o'z ichiga olgan ruchka shaklidagi applikator BL-5010ni ishlab chiqadi. BioLineRx Ltd. 2003 yilda tashkil etilgan va shtab-kvartirasi Isroilning Hevel Modi'in shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ella Sorani Ph.D. | Chief Development Officer |
| Mr. John Lacey | Head of Corporate Communications & Investor Relations |
| Mr. Philip A. Serlin CPA, M.B.A. | Chief Executive Officer |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director |
| Ms. Mali Zeevi CPA | Chief Financial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-28 | 6-K | zk2635143.htm |
| 2026-03-27 | 20-F/A | zk2634966.htm |
| 2026-03-26 | 6-K | zk2634945.htm |
| 2026-03-23 | 6-K | zk2634888.htm |
| 2026-03-23 | 20-F | zk2634707.htm |
| 2026-02-23 | 6-K | zk2634422.htm |
| 2026-01-23 | S-8 | zk2634171.htm |
| 2025-11-24 | 6-K | zk2534058.htm |
| 2025-11-17 | 6-K | zk2534026.htm |
| 2025-09-29 | 6-K | zk2533810.htm |